Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph not_applicable

33%

Ph phase_2

33%

Ph early_phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(1)

Detailed Status

Recruiting1

Terminated1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (33.3%)

Phase 21 (33.3%)

N/A1 (33.3%)

Trials by Status

recruiting133%

terminated133%

completed133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_2

Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection

NCT07046910

terminatedearly_phase_1

HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease

NCT02638519

completednot_applicable

Bronchopulmonary Dysplasia: From Neonatal Chronic Lung Disease to Early Onset Adult COPD

NCT02723513

Clinical Trials (3)

Showing 3 of 3 trials

NCT07046910Phase 2

Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection

Recruiting

NCT02638519Early Phase 1

HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease

Terminated

NCT02723513Not Applicable

Bronchopulmonary Dysplasia: From Neonatal Chronic Lung Disease to Early Onset Adult COPD

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3